Drug intelligence / Profile preview

BWC5681

Development stage: Preclinical
Lead developer: Bugworks Research
Modality: Small Molecules
Administration: Oral

Overview

BWC5681 (also known as BWC6388) is a preclinical small molecule dual inhibitor of cyclin-dependent kinase 7 (CDK7) and cyclin-dependent kinase 2 (CDK2), developed by Bugworks Research. It is designed as a dual transcription and cell-cycle control strategy to target aggressive, transcription-addicted, and replication-stress-driven tumors. The CDK2-inhibiting component is intended to address cyclin-E/CDK2-driven resistance biology. BWC5681 is being investigated for the treatment of triple-negative breast cancer (TNBC), ovarian cancer, prostate cancer, lung cancer, and other MYC- or CCNE-driven malignancies.

Targets

CDK2 (Cyclin-dependent kinase 2)CDK7

Beyond the preview

Go deeper on BWC5681.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWC5681.

Explore the full profile